Loading company…
Israel-based biopharmaceutical company developing and commercializing enzyme replacement therapies for rare diseases.
Founded in 1993 in Karmiel, Israel, Protalix BioTherapeutics Inc. develops and commercializes enzyme replacement therapies for patients with rare genetic disorders. It became public through a reverse merger with Orthodontix, Inc. in December 2006. The company has raised a total of USD 40.00 mn, most recently in a PIPE round in which Cybele Holdings participated, and reported USD 38.35 mn in revenue for 2023 with an EBITDA of USD -16.67 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in